Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists

VIRI - Virios Therapeutics, LLC Stock Price, Fair Value and News

$5.01+0.20 (+4.16%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

VIRI Price Action

Last 7 days

2.5%

Last 30 days

3.1%

Last 90 days

2.2%

Trailing 12 Months

-0.8%

VIRI RSI Chart

Dec2025FebMarAprMayJunJulAugSep020406080100

VIRI Valuation

Market Cap

9.6M

Price/Earnings (Trailing)

-0.39

Price/Sales (Trailing)

8.02

EV/EBITDA

0.17

Price/Free Cashflow

-0.61

VIRI Price/Sales (Trailing)

2024AprJulOct2025AprJul020406080100120

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

VIRI Fundamentals

VIRI Revenue

Revenue (TTM)

1.2M

OctNovDec1.156443M

VIRI Earnings

Earnings (TTM)

-24.7M

Earnings Growth (Yr)

-262.66%

Earnings Growth (Qtr)

65.15%

20212022202320242025-25M-20M-15M-10M-5M

VIRI Profitability

EBT Margin

-2122.95%

Return on Equity

-359.68%

Return on Assets

-25.59%

Free Cashflow Yield

-164.5%

VIRI Investor Care

Shares Dilution (1Y)

72.12%

Diluted EPS (TTM)

-20.09

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Dec1.156443M
Net sales
YearQ1Q2Q3Q4
20230001.2M
Get all data in R, Python etc through our Historical Stock Data APIs

About Virios Therapeutics, LLC

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.
 CEO
 WEBSITEvirios.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES4

Virios Therapeutics, LLC Frequently Asked Questions

What is the ticker symbol for Virios Therapeutics, LLC? What does VIRI stand for in stocks?

VIRI is the stock ticker symbol of Virios Therapeutics, LLC. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Virios Therapeutics, LLC (VIRI)?

As of Fri Sep 19 2025, market cap of Virios Therapeutics, LLC is 9.57 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VIRI stock?

You can check VIRI's fair value in chart for subscribers.

Is Virios Therapeutics, LLC a good stock to buy?

The fair value guage provides a quick view whether VIRI is over valued or under valued. Whether Virios Therapeutics, LLC is cheap or expensive depends on the assumptions which impact Virios Therapeutics, LLC's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VIRI.

What is Virios Therapeutics, LLC's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Sep 19 2025, VIRI's PE ratio (Price to Earnings) is -0.39 and Price to Sales (PS) ratio is 8.02. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VIRI PE ratio will change depending on the future growth rate expectations of investors.